Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 2, 2011, Pages 445-452

  Rodrigues, George ^a,k   Bae, Kyounghwa ^b   Roach, MacK ^c   Lawton, Colleen ^d   Donnelly, Bryan ^e   Grignon, David ^f   Hanks, Gerald ^g   Porter, Arthur ^h   Lepor, Herbert ⁱ   Sandler, Howard ^j  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f Indiana Forensic Institute   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k LONDON REGIONAL CANCER PROGRAM   (Canada)

more..

Author keywords

Clinical trials; External beam radiation therapy; Hormonal therapy; Outcomes; Prognostic factors; Prostate cancer

Indexed keywords

CLINICAL TRIAL; EXTERNAL BEAM RADIATION THERAPY; HORMONAL THERAPY; OUTCOMES; PROGNOSTIC FACTORS; PROSTATE CANCER;

DISEASES; EXPERIMENTS; ONCOLOGY; REGRESSION ANALYSIS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISTANT METASTASIS; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; ONCOLOGY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79955578017     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.02.034     Document Type: Article

References (30)

1. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300 (Pubitemid 27318990)
2. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
3. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
4. E.M. Messing, J. Manola, and M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
5. C. Bastide, R. Kuefer, and M. Loeffler The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml Prostate Cancer Prostatic Dis 9 2006 239 244 (Pubitemid 44317257)
6. D.W. Brandli, M.O. Koch, R.S. Foster, R. Bihrle, and T.A. Gardner Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy BJU Int 92 2003 19 22
7. T.M. Pisansky, M.J. Kahn, and G.M. Rasp A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma Cancer 79 1997 337
8. A.W. Partin, M.W. Kattan, and E.N.P. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
9. H. Lukka, P. Warde, and T. Pickles Controversies in prostate cancer radiotherapy: Consensus development Can J Urol 8 2001 1314 1322
10. Y.C. Ou, J.T. Chen, C.L. Cheng, H.C. Ho, and C.R. Yang Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml Jpn J Clin Onc 33 2003 574 579
11. E. Wiebe, G. Rodrigues, M. Lock, D. D'Souza, and L. Stitt Outcome analysis of prostate cancer patients with pretreatment PSA greater than 50 ng/ml Can J Urol 15 3 2008 3703 3708
12. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
13. M.R. Cooperberg, J. Cowan, J.M. Broering, and P.R. Carroll High-risk prostate cancer in the United States, 1990-2007 World J Urol 26 2008 211 218
14. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655 (Pubitemid 47418390)
15. M. Roach III, M. DeSilvio, and R. Valicenti Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int J Radiat Oncol Biol Phys 66 2006 647 653 (Pubitemid 44436716)
16. M. Roach III, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
17. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
18. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
19. C.T. Smith, P.R. Williamson, and A.G. Marson Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes Stat Med 24 2005 1307 1319 (Pubitemid 40585170)
20. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
21. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
22. J.D. Kalbfleisch, and R.L. Prentice The statistical analysis of failure time data 1980 John Wiley & Sons New York
23. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
24. D.R. Cox Regression models and life tables J Royal Stat Soc 34 1972 187 202
25. J. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
26. M. Roach Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 1923 1924
27. M. Roach, C. Marquez, and H. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1993 33 37 (Pubitemid 24012852)
28. R.G. Stock, A. Ho, J.A. Cesaretti, and N.N. Stone Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control Int J Radiat Oncol Biol Phys 66 2006 389 394 (Pubitemid 44332760)
29. B.P. Vanasupa, E.L. Paquette, and H. Wu The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL Urol Oncol 7 2002 167 172
30. M. Roach III, J. Lu, and M.V. Pilepich Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627 (Pubitemid 30317479)